The Performance of Multi-tracer Multimodality PET in Lymphoma
NCT05004961 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2023-03-03
Summary
Investigating the performance of Multi-tracer Multimodality PET in lymphoma
Conditions
- Positron-Emission Tomography
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
lead OTHER
Principal Investigators
-
Yang Zhi, PhD · Peking University Cancer Hospital & Institute
Eligibility
- Min Age
- 15 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-15
- Primary Completion
- 2023-08-15
- Completion
- 2023-12-31
Countries
- China
Study Locations
More Related Trials
-
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
NCT04317313 ·Status: COMPLETED
-
PET-CT in Lymphoma Among the Eldery
NCT07259941 ·Status: NOT_YET_RECRUITING
-
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
NCT04367948 ·Status: UNKNOWN ·Phase: NA
-
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
NCT06795113 ·Status: RECRUITING
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
NCT02931201 ·Status: UNKNOWN ·Phase: NA
-
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma
NCT05411250 ·Status: UNKNOWN
-
Total-body PET / CT in the Evaluation of Treatment and Prognosis of Lymphoma
NCT04931875 ·Status: UNKNOWN
-
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
NCT00534989 ·Status: COMPLETED ·Phase: NA
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
NCT03051568 ·Status: UNKNOWN ·Phase: NA
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
NCT03051542 ·Status: UNKNOWN ·Phase: NA
-
PET/CT Vs Bone Marrow Biopsy in Exclusion of Bone Marrow Infiltration for Initial Staging of Lymphoma
NCT05565898 ·Status: NOT_YET_RECRUITING
-
BBPA PET/CT in Patients With Malignant Tumors
NCT05987098 ·Status: RECRUITING ·Phase: NA
-
PD-L1 Targeting Molecular Imaging of Solid Tumors
NCT04629326 ·Status: RECRUITING ·Phase: NA
-
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NCT05662540 ·Status: RECRUITING ·Phase: NA
-
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
NCT00498667 ·Status: WITHDRAWN
-
Study of the Angiogenesis by PET/CT in Patients With Lymphoma
NCT02490891 ·Status: COMPLETED ·Phase: PHASE2
-
Positron Emission Tomography(PET) in Lymphoma Assessment
NCT00887718 ·Status: COMPLETED ·Phase: NA
-
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441 ·Status: NOT_YET_RECRUITING
-
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL
NCT05113576 ·Status: COMPLETED
-
The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma
NCT03973164 ·Status: COMPLETED
-
FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma
NCT05186610 ·Status: COMPLETED
-
TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors
NCT06755086 ·Status: NOT_YET_RECRUITING
-
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
NCT07319897 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma
NCT00530179 ·Status: COMPLETED ·Phase: NA
-
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
NCT05321316 ·Status: RECRUITING ·Phase: NA